No connection

Search Results

CCEL vs JNJ

CCEL
Cryo-Cell International, Inc.
BEARISH
Price
$3.67
Market Cap
$29.6M
Sector
Healthcare
AI Confidence
95%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CCEL
--
JNJ
21.55
Forward P/E
CCEL
183.5
JNJ
18.9
P/B Ratio
CCEL
-1.61
JNJ
7.03
P/S Ratio
CCEL
0.95
JNJ
6.09
EV/EBITDA
CCEL
31.86
JNJ
17.81

Profitability

Gross Margin
CCEL
63.53%
JNJ
68.08%
Operating Margin
CCEL
9.96%
JNJ
23.97%
Profit Margin
CCEL
-8.52%
JNJ
28.46%
ROE
CCEL
--
JNJ
35.03%
ROA
CCEL
0.19%
JNJ
8.68%

Growth

Revenue Growth
CCEL
-3.6%
JNJ
9.1%
Earnings Growth
CCEL
-80.5%
JNJ
48.6%

Financial Health

Debt/Equity
CCEL
--
JNJ
0.6
Current Ratio
CCEL
0.62
JNJ
1.03
Quick Ratio
CCEL
0.55
JNJ
0.69

Dividends

Dividend Yield
CCEL
16.35%
JNJ
2.19%
Payout Ratio
CCEL
3962.91%
JNJ
46.6%

AI Verdict

CCEL BEARISH

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Strengths
Strong gross margins at 63.53%
Positive operating margin of 9.96%
Low Price/Sales ratio of 0.95
Risks
Negative equity as indicated by Price/Book ratio of -1.61
Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55
Unsustainable dividend payout ratio (3962.91%)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

CCEL vs JNJ: Head-to-Head Comparison

This page compares Cryo-Cell International, Inc. (CCEL) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile